S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood

Thrombosis Research

Volumn 122, Issue 2, 2008, Pages 265-270

  Rupin, Alain ^a   Gaertner, Roger ^a   Mennecier, Philippe ^a   Richard, Isabelle ^a   Benoist, Alain ^a   De Nanteuil, Guillaume ^a   Verbeuren, Tony J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antithrombotics; Fibrinolysis; inhibitor; PAI 1; Thrombolysis

Indexed keywords

BENZOTHIOPHENE DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR; S 35225; TIPLAXTININ; WAY 140312;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

ANIMALS; BIPHENYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLEACETIC ACIDS; INFUSIONS, INTRAVENOUS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RECOMBINANT PROTEINS; RISK; THIOPHENES; THROMBOSIS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 44549084070     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.11.006     Document Type: Article

References (28)

1. Aso Y., Matsumoto S., Fujiwara Y., Tayama K., Inukai T., and Takemura Y. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism 51 (2002) 471-476
2. Poli K.A., Tofler G.H., Larson M.G., Evans J.C., Sutherland P.A., Lipinska I., et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 101 (2000) 264-269
3. Urano T., Kojima Y., Takahashi M., Serizawa K., Sakakibara K., Takada Y., et al. Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma. Jpn J Physiol 43 (1993) 221-228
4. Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2 (1987) 3-9
5. Thogersen A.M., Jansson J.H., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
6. Wiman B., Andersson T., Hallqvist J., Reuterwall C., Ahlbom A., and deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 20 (2000) 2019-2023
7. Marcucci R., Brogi D., Sofi F., Giglioli C., Valente S., Alessandrello L.A., et al. PAI-1 and homocysteine, but not lipoprotein (a) nor thrombophilic polymorphism, are associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart 92 (2006) 377-381
8. Eren M., Painter C.A., Atkinson J.B., Declerck P.J., and Vaughan D.E. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106 (2002) 491-496
9. Erickson L.A., Fn ici G.J., Lund J.E., Boyle T.P., Polites H.G., and Marotti K.R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 346 (1990) 74-76
10. Carmeliet P., Stassen J.M., Schoonjans L., Ream B., van den Oord J.J., De Mol M., et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92 (1993) 2756-2760
11. Eitzman D.T., Westrick R.J., Nabel E.G., and Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 95 (2000) 577-580
12. Kawasaki T., Dewerchin M., Lijnen H.R., Vermylen J., and Hoylaerts M.F. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 96 (2000) 153-160
13. Eitzman D.T., Westrick R.J., Xu Z., Tyson J., and Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96 (2000) 4212-4215
14. Charlton P.A., Faint R.W., Bent F., Bryans J., Chicarelli-Robinson I., Mackie I., et al. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost 75 (1996) 808-815
15. Crandall D.L., Hennan J.K., Elokdah H., Krishnamurthy G., Antrilli T.M., Bauer J.S., et al. WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation. Biochem Biophys Res Commun 311 (2003) 904-908
16. Crandall D.L., Elokdah H., Di L., Hennan J.K., Gorlatova N.V., and Lawrence D.A. Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost 2 (2004) 1422-1428
17. Elokdah H., Abou-Gharbia M., Hennan J.K., McFarlane G., Mugford C.P., Krishnamurthy G., et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 47 (2004) 3491-3494
18. Friederich P.W., Levi M., Biemond B.J., Charlton P., Templeton D., van Zonneveld A.J., et al. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 96 (1997) 916-921
19. Gils A., Stassen J.M., Nar H., Kley J.T., Wienen W., Ries U.J., et al. Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb Haemost 88 (2002) 137-143
20. Liang A., Wu F., Tran K., Jones S.W., Deng G., Ye B., et al. Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res 115 (2005) 341-350
21. De Nanteuil G., Lila-Ambroise C., Rupin A., Vallez M.O., and Verbeuren T.J. New fibrinolytic agents: benzothiophene derivatives as inhibitors of the t-PA-PAI-1 complex formation. Bioorg Med Chem Lett 13 (2003) 1705-1708
22. Hoylaerts M., Rijken D.C., Lijnen H.R., and Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257 (1982) 2912-2919
23. Stringer H.A., and Pannekoek H. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis. J Biol Chem 270 (1995) 11205-11208
24. Hu B., Jetter J.W., Wrobel J.E., Antrilli T.M., Bauer J.S., Di L., et al. Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1. Bioorg Med Chem Lett 15 (2005) 3514-3518
25. Gorlatova N.V., Cale J.M., Elokdah H., Li D., Fan K Warnock M., Crandall D.L., et al. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 282 (2007) 9288-9296
26. Hennan J.K., Elokdah H., Leal M., Ji A., Friedrichs G.S., Morgan G.A., et al. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 314 (2005) 710-716
27. Smith L.H., Dixon J.D., Stringham J.R., Eren M., Elokdah H., Crandall D.L., et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 107 (2006) 132-134
28. Crandall D.L., Quinet E.M., El Ayachy S., Hreha A.L., Leik C.E., Savio D.A., et al. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 26 (2006) 2209-2215